Alain Lortholary - Concepedia

Author

Alain Lortholary

Also Known As

A Lortholary, A. Lortho-lary, A. Lortholary, A. lortholary, Alain H. Lortholary, Alain LORTHOLARY, Alain Lortholary, B. Weber, C Veyret, Catherine Noguès

382

Publications

17.9K

Citations

H-Index

Concepts

All Affiliations

Institut Gustave Roussy Centre Léon Bérard Institut Curie Inserm Hôpital privé du Confluent

About

Alain Lortholary is an author at Institut Gustave Roussy specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	32	64	7.6K
2	Health Sciences	10	10	520
3	Cell Biology	3	3	72
4	Public Health	2	2	83
5	Biostatistics	1	1	125

Alain Lortholary

115

Publications

16.3K

Citations

H-Index

Page 1

	Year	Citations
A Phase 3 Trial of Bevacizumab in Ovarian Cancer Timothy Perren, Ann Marie Swart, Jacobus Pfisterer, New England Journal of Medicine	2011	2.1K
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer Isabelle Ray‐Coquard, Patricia Pautier, Sandro Pignata, New England Journal of Medicine	2019	1.9K
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial Éric Pujade-Lauraine, Jonathan A. Ledermann, Frédèric Selle, The Lancet Oncology Brca1/2 MutationMedicineCancer ManagementGynecologyOlaparib Tablets	2017	1.8K
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial Robert L. Coleman, Amit M. Oza, Domenica Lorusso, The Lancet Rucaparib Maintenance TreatmentMedicineRecurrent Ovarian CarcinomaGynecologyCancer Treatment	2017	1.7K
Zoledronic Acid Is Superior to Pamidronate in the Treatment of Hypercalcemia of Malignancy: A Pooled Analysis of Two Randomized, Controlled Clinical Trials Pierre Major, Alain Lortholary, Jeremy K. Hon, Journal of Clinical Oncology	2001	851
Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse Éric Pujade-Lauraine, Uwe Wagner, Elisabeth Aavall-Lundqvist, Journal of Clinical Oncology	2010	558
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer Charles E. Geyer, Judy E. Garber, Richard D. Gelber, Annals of Oncology Breast OncologyOverall SurvivalMedicinePathologyGermline Pathogenic Variants	2022	404
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial Andrés Poveda, Anne Floquet, Jonathan A. Ledermann, The Lancet Oncology	2021	391
6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial X. Pivot, Gilles Romieu, Marc Debled, The Lancet Oncology Breast OncologyMedicineRandomised Phase 3Clinical TrialsBreast Cancer	2013	337
Trastuzumab for Patients With Axillary-Node–Positive Breast Cancer: Results of the FNCLCC-PACS 04 Trial M. Spielmann, Henri Roché, T. Delozier, Journal of Clinical Oncology	2009	298

Page 1